Research and Development Expenses Breakdown: Dr. Reddy's Laboratories Limited vs Apellis Pharmaceuticals, Inc.

R&D Spending: Dr. Reddy's vs. Apellis - A Decade of Innovation

__timestampApellis Pharmaceuticals, Inc.Dr. Reddy's Laboratories Limited
Wednesday, January 1, 2014837952212402000000
Thursday, January 1, 20151373031117449000000
Friday, January 1, 20162297859917834000000
Sunday, January 1, 20174030387819551000000
Monday, January 1, 201810528557618265000000
Tuesday, January 1, 201922096877015607000000
Wednesday, January 1, 202029992100015410000000
Friday, January 1, 202142086900016541000000
Saturday, January 1, 202238723600017482000000
Sunday, January 1, 202335438700019381000000
Monday, January 1, 202422873000000
Loading chart...

In pursuit of knowledge

A Decade of R&D: Dr. Reddy's vs. Apellis Pharmaceuticals

In the ever-evolving pharmaceutical industry, research and development (R&D) expenses are a critical indicator of innovation and growth. Over the past decade, Dr. Reddy's Laboratories Limited and Apellis Pharmaceuticals, Inc. have shown contrasting R&D investment strategies. Dr. Reddy's, a global player, consistently invested heavily, with expenses peaking at approximately $19.4 billion in 2023, reflecting a steady commitment to innovation. In contrast, Apellis, a relatively newer entrant, demonstrated a rapid increase in R&D spending, growing from a modest $8.4 million in 2014 to a significant $420 million in 2021, before slightly declining. This trend highlights Apellis's aggressive push towards innovation, despite its smaller scale. Notably, data for Apellis in 2024 is missing, indicating potential shifts in strategy. These insights underscore the dynamic nature of R&D investments in the pharmaceutical sector, where strategic spending can define market leadership.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025